Summary of Drug Abuse “Rates” in the United States: Focus on Morphine Catherine Dormitzer, PhD, MPH Division of Epidemiology Office of Surveillance and.

Slides:

Advertisements

Similar presentations

A healthier and safer Indiana A STHMA I N I NDIANA Amy Brandt, MPHChronic Respiratory Disease Epidemiologist Indiana State Department of Health C HRONIC.

Advertisements

Confidence Intervals Objectives: Students should know how to calculate a standard error, given a sample mean, standard deviation, and sample size Students.

Inferences based on TWO samples

San Francisco Bay Area Drug Trends and Effective Intervention Strategies Alice Gleghorn, Ph.D County Alcohol and Drug Program Administrator San Francisco.

National Institute on Drug Abuse P rescription D rug A buse: An Escalating Public Health Threat P rescription D rug A buse: An Escalating Public Health.

Exploring Multiple Dimensions of Asthma Disparities Using the Behavioral Risk Factor Surveillance System Kirsti Bocskay, PhD, MPH Office of Epidemiology.

1 1 Slide IS 310 – Business Statistics IS 310 Business Statistics CSU Long Beach.

1 Copyright © 2010, 2007, 2004 Pearson Education, Inc. All Rights Reserved. Section 7.3 Estimating a Population mean µ (σ known) Objective Find the confidence.

William A. Lanier, DVM, MPH Kristina Russell, MPH Utah Department of Health Risk Factors for Prescription Opioid Death – Utah, 2008–2009 Office of Surveillance,

Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees November 13 & 14, 2008 Reported Manipulation of Oxycodone Extended-Release.

Anesthetic and Life Support Drugs, and Drug Safety and Risk Management Advisory Committees, November 13, 2008 Outpatient Drug Utilization Trends for Oxycodone.

10-1 Introduction 10-2 Inference for a Difference in Means of Two Normal Distributions, Variances Known Figure 10-1 Two independent populations.

Mean for sample of n=10 n = 10: t = 1.361df = 9Critical value = Conclusion: accept the null hypothesis; no difference between this sample.

Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees May 5, 2008 Reported Manipulation of OxyContin Tablets LCDR Kristina.

Pengujian Hipotesis Proporsi dan Beda Proporsi Pertemuan 21 Matakuliah: I0134/Metode Statistika Tahun: 2007.

1 (Student’s) T Distribution. 2 Z vs. T Many applications involve making conclusions about an unknown mean . Because a second unknown, , is present,

1 Copyright © 2010, 2007, 2004 Pearson Education, Inc. All Rights Reserved. Section 7.2 Estimating a Population Proportion Objective Find the confidence.

Prescription Opioid Use and Opioid-Related Overdose Death — TN, 2009–2010 Jane A.G. Baumblatt, MD Centers for Disease Control and Prevention Epidemic Intelligence.

HaDPop Measuring Disease and Exposure in Populations (MD) &

Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees, November 13 & 14, 2008 History of OxyContin: Labeling and Risk.

Prescription Drug Abuse Sharon Hertz, M.D. Medical Officer Division of Anesthetic, Critical Care and Addiction Drug Products Food and Drug Administration.

Are exposures associated with disease?

Abuse Liability of Hydromorphone Extended Release Capsules Silvia N. Calderon, Ph.D. Controlled Substance Staff Center for Drug Evaluation and Research.

1 National Estimates from the Drug Abuse Warning Network CAPT Kathy Poneleit United States Public Health Service Office of Applied Studies Substance Abuse.

1/2555 สมศักดิ์ ศิวดำรงพงศ์

1 1 Slide © 2005 Thomson/South-Western Chapter 9, Part B Hypothesis Tests Population Proportion Population Proportion Hypothesis Testing and Decision Making.

Gil Harari Statistical considerations in clinical trials

Sullivan – Fundamentals of Statistics – 2 nd Edition – Chapter 11 Section 2 – Slide 1 of 25 Chapter 11 Section 2 Inference about Two Means: Independent.

1/26/09 1 Community Health Assessment in Small Populations: Tools for Working With “Small Numbers” Region 2 Quarterly Meeting January 26, 2009.

Health and Disease in Populations 2001 Sources of variation (2) Jane Hutton (Paul Burton)

In Hospital Hip Fracture Mortality Colleen McLaughlin, MPH, PhD Division of Quality and Patient Safety.

Basic Business Statistics, 11e © 2009 Prentice-Hall, Inc. Chap 8-1 Confidence Interval Estimation.

Business Statistics: A Decision-Making Approach, 7e © 2008 Prentice-Hall, Inc. Chap 11-1 Business Statistics: A Decision-Making Approach 7 th Edition Chapter.

Excel Simple Computation. Compute the Mean Place the cursor over a cell, click, and type. Pressing the enter key moves to the next cell. Here I typed.

Normal Distributions Z Transformations Central Limit Theorem Standard Normal Distribution Z Distribution Table Confidence Intervals Levels of Significance.

Available Types of National Drug Use Data DSARM Advisory Committee Meeting Silver Spring, Maryland May 18, 2005 Judy Staffa, PhD, RPh, Epidemiology Team.

Presented by Terance Woodworth, M.S. at the September 9, 2003 meeting of the Anesthetic and Life Support Drugs Advisory Committee.

Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November |1 | Prequalification programme: Priority.

1 Findings from the Drug Abuse Warning Network Judy K. Ball, Ph.D., M.P.A. Office of Applied Studies Substance Abuse and Mental Health Services Administration.

The National Crisis of Prescription Opiate Abuse: How can the FDA respond? Anesthetic & Life Support Drugs Advisory Committee March 29, 2007 Art Van Zee,MD.

Guidance Update: Average, Population, and Individual Approaches to Establishing Bioequivalence Mei-Ling Chen, Ph.D. Associate Director Office of Pharmaceutical.

State of the State in outcomes: Prescription drug overdoses Karin A. Mack, PhD Senior Behavioral Scientist Prescription Drug Overdose Team National Center.

Comparing Two Proportions. AP Statistics Chap 13-2 Two Population Proportions The point estimate for the difference is p 1 – p 2 Population proportions.

FDA Anesthetic & Life Support Drugs Advisory Committee Sept. 10, 2003 Art Van Zee,MD St. Charles Clinic St. Charles, Va.

Lecture 4 Confidence Intervals. Lecture Summary Last lecture, we talked about summary statistics and how “good” they were in estimating the parameters.

Risk Management of Modified- Release Opiate Analgesics: Palladone Sharon Hertz, M.D. Medical Team Leader, Analgesics Division of Anesthetic, Critical Care,

Module 25: Confidence Intervals and Hypothesis Tests for Variances for One Sample This module discusses confidence intervals and hypothesis tests.

1 National Estimates from the Drug Abuse Warning Network Judy K. Ball, Ph.D., M.P.A. Office of Applied Studies Substance Abuse and Mental Health Services.

Hypothesis Testing. Suppose we believe the average systolic blood pressure of healthy adults is normally distributed with mean μ = 120 and variance σ.

Ex St 801 Statistical Methods Inference about a Single Population Mean (CI)

Evaluation of a Scaling Approach for Highly Variable Drugs Sam H. Haidar, Ph.D., R.Ph. Office of Generic Drugs Advisory Committee for Pharmaceutical Sciences.

Statistical Criteria for Establishing Safety and Efficacy of Allergenic Products Tammy Massie, PhD Mathematical Statistician Team Leader Bacterial, Parasitic.

Mortality Associated with Dextromethorphan Elizabeth H. Crane, Ph.D., M.P.H. CAPT Kathy Poneleit, M.P.H. Office of Applied Studies, SAMHSA American Public.

Findings from the Drug Abuse Warning Network Immediate and Sustained Release Opioid Analgesics Judy K. Ball, Ph.D., M.P.A. Office of Applied Studies, Substance.

Parameter Estimation.

Comparing Two Proportions

Math 4030 – 10b Inferences Concerning Variances: Hypothesis Testing

Comparing abuse of extended-release versus immediate-release opioid analgesics adjusted for number of prescriptions and morphine-equivalent dose Stephen.

Confidence Intervals and Hypothesis Tests for Variances for One Sample

SAMPLE SIZE DETERMINATION

Rounding and estimating: Upper and Lower Bounds (sig figs)

St. Edward’s University

Available Types of National Drug Use Data

Descriptive vs. Inferential

Chapter 10 Inferences on Two Samples

Slides by JOHN LOUCKS St. Edward’s University.

Epidemiology MPH 531 Analytic Epidemiology Case control studies

Chapter 12 Inference for Proportions

Rounding and estimating: Upper and Lower Bounds

Chapter 9 Lecture 4 Section: 9.4.

Presentation transcript:

Summary of Drug Abuse “Rates” in the United States: Focus on Morphine Catherine Dormitzer, PhD, MPH Division of Epidemiology Office of Surveillance and Epidemiology Catherine Dormitzer, PhD, MPH Division of Epidemiology Office of Surveillance and Epidemiology Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees, November 14, 2008

2 OverviewOverview Background Methods Summary of calculations Conclusions Background Methods Summary of calculations Conclusions Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees, November 14, 2008

3 Background/MethodsBackground/Methods Numerator data –Non-medical Use ED Visits (DAWN) Denominator data –Retail prescriptions (SDI) used as proxy for drug availability Calculated estimates per 10,000 retail prescriptions Numerator data –Non-medical Use ED Visits (DAWN) Denominator data –Retail prescriptions (SDI) used as proxy for drug availability Calculated estimates per 10,000 retail prescriptions Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees, November 14, 2008

4 LimitationsLimitations Calculating estimates using data from different sources –Sampling methodologies –No confidence intervals –Populations –Data are not linked Calculating estimates using data from different sources –Sampling methodologies –No confidence intervals –Populations –Data are not linked Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees, November 14, 2008

SAMHSA/OAS Morphine, CR vs. IR – Nonmedical Use Source: DAWN estimates for the U.S., *Significant change, 2004 vs vs No significant change 2006 vs. 2007

6 Projected Retail Prescriptions Dispensed for Morphine by Release Type, SDI Vector One™: National (VONA)., Extracted Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees, November 14, 2008

7 Sources: National estimates from DAWN, ; SDI VONA Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees, November 14, 2008 Ratios: Non-Medical Use ED Visits per 10,000 Retail Prescriptions, Morphine by Release Type, ED Visits per 10,000 prescriptions

8 SummarySummary These data are intended to be descriptive and qualitative. Statistical attributes such as confidence intervals would be required to form more definitive conclusions. Ratios of non-medical use of morphine appear to be considerably higher for immediate release products versus extended release products. These data are intended to be descriptive and qualitative. Statistical attributes such as confidence intervals would be required to form more definitive conclusions. Ratios of non-medical use of morphine appear to be considerably higher for immediate release products versus extended release products. Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees, November 14, 2008

Questions?Questions?

Back-Up Slides Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees, November 14, 2008

SAMHSA/OAS Nonmedical Use of Pharmaceuticals, Selected Opiates/Opioids, 2007 Source: National estimates from DAWN, 2007 * Single- & multi-ingredient formulations CI lower bound Estimate CI upper bound

12 Projected Retail Prescriptions Dispensed for Selected Opioids, 2007 SDI Vector One™: National (VONA). Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees, November 14, 2008

13 DAWN: Non-Medical Use ED Visits per 10,000 Retail Prescriptions: 2007 * Includes all formulations Source: National estimates from DAWN, 2007; SDI VONA Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees, November 14, 2008